Ani Pharmaceutic Stock Price, News & Analysis

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) has announced that CEO Nikhil Lalwani and CFO Stephen Carey will present at the Cantor Virtual Global Healthcare Conference on September 30, 2021, at 8:00 a.m. ET. The presentation will be available via a live webcast and archived for 30 days on the Company's website under the Investors section. ANI Pharmaceuticals is dedicated to developing, manufacturing, and marketing quality pharmaceutical products, focusing on sustainable growth through its Purified Cortrophin Gel® franchise and generics business.

ANI Pharmaceuticals has launched its generic version of Bystolic, called Nebivolol Tablets, available in 2.5 mg, 5 mg, 10 mg, and 20 mg dosages. The U.S. market for Bystolic is approximately $1.05 billion. The launch was executed simultaneously from two manufacturing sites, demonstrating ANI's supply chain capabilities. Nebivolol is prescribed for treating hypertension and can be used alone or with other medications. The company emphasizes its commitment to sustainable growth through its generics division and innovative product development.

ANI Pharmaceuticals announced that the FDA has accepted its supplemental New Drug Application for Purified Cortrophin Gel. This is a significant milestone with a target action date set for October 29, 2021. The company plans to launch this second ACTH-based treatment, which is vital for patients with chronic autoimmune disorders like multiple sclerosis and rheumatoid arthritis. ANI Pharmaceuticals aims to strengthen its market position through this new drug while continuing to enhance its generics business.

ANI Pharmaceuticals reported financial results for Q2 2021, with net revenues at $48.6 million, slightly up from $48.5 million in Q2 2020. The net loss for the quarter was $14.1 million, compared to $12.3 million the previous year. Key highlights include the refiling of the sNDA for Cortrophin® Gel and the ongoing acquisition of Novitium Pharma, expected to close later this year. Despite increased revenues from generic and branded products, operating expenses rose to $64.2 million, impacting profitability. The company held $24.3 million in cash and cash equivalents, with total debt of $205.7 million.

ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will release its second quarter 2021 financial results on August 6, 2021. A conference call is scheduled for 8:30 a.m. ET, led by CEO Nikhil Lalwani and CFO Stephen P. Carey. Participants can join via a toll-free number or access the live webcast on the company's website. A replay will be available shortly after the call and for one week. ANI specializes in developing high-quality branded and generic pharmaceuticals, focusing on niche markets like controlled substances and oncology products.

ANI Pharmaceuticals (Nasdaq: ANIP) has re-filed its supplemental new drug application (sNDA) for Cortrophin® Gel with the FDA. CEO Nikhil Lalwani expressed satisfaction with the re-filing process, highlighting the company's extensive efforts to address previous FDA feedback through expert consultations. Cortrophin Gel is considered a key product for ANI, with hopes for market approval to benefit patients. The company specializes in developing and marketing specialty pharmaceuticals, focusing on niche markets.

ANI Pharmaceuticals will present at the Raymond James Human Health Innovation Conference on June 22, 2021, at 12:00 PM Eastern Time. The presentation, featuring CEO Nikhil Lalwani and CFO Stephen Carey, will be available via webcast and archived for 30 days. ANI focuses on delivering high-quality specialty pharmaceuticals, including controlled substances and oncology products. More about the company can be found at www.anipharmaceuticals.com.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced log-in details for its 2021 Virtual Annual Meeting of Stockholders on June 2, 2021, at 10 a.m. Eastern Time. Stockholders of record as of April 26, 2021, can vote and submit questions during the meeting via a provided control number. Participants can log in starting at 9:45 a.m. An annual meeting replay will be available for one year. ANI is a specialty pharmaceutical company focusing on the development and manufacturing of branded and generic prescription pharmaceuticals, including narcotics and oncolytics.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) announced that CEO Nikhil Lalwani and CFO Stephen Carey will present at the Jefferies Virtual Healthcare Conference on June 4, 2021, at 10:00 a.m. ET. The presentation will be webcast live and archived for 30 days on the Company's website. ANI is an integrated specialty pharmaceutical company focused on developing and marketing high-quality branded and generic prescription pharmaceuticals, particularly in niche markets.